Are you paying twice for GLP-1s—once for the medications and then again due to low adherence?
This new report examines what causes the double-spend and how to stop it—all while optimizing the positive impact GLP-1s can have on population health and long-term claims costs.
Key insights inside:
- The hidden "double spend" in many GLP-1 strategies
- Why medication-only approaches often fall short
- How integrated behavioral and clinical support improves outcomes